News

Zealand Pharma, a Denmark-based biopharmaceutical company, has advanced ZP1848, a glucagon-like peptide-2 agonist, into Phase I clinical trials. ZP1848, a peptide which incorporates the company’s proprietary SIP technology,

Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing, with high content phenotypic analyses in what will be a genome-scale screen using cultured

Revenues for the fourth quarter down 2% from the previous year, totaling $396.8 million. Excluding a 4% unfavorable impact from changes in foreign currency, revenues in the quarter

The Carillon system is a percutaneous treatment for functional mitral regurgitation. The CE Mark approval is an important milestone for Cardiac Dimensions, allowing the company to market the

According to the company, the new strategic business unit (SBU) is dedicated to advancing the field of interventional radiology through significant investments in the development of new medical

This is in addition to having already received the FDA’s clearance to market the company’s patented Microwave coagulation/ablation system for surgical applications. The system and single patient use

According to the company, there is a significant need for the Premier Campy test because it provides a solution to several concerns associated with culture testing, currently the

Approximately eight healthy volunteers came for two visits, with two different formulations. The insulin suppositories showed rapid insulin absorption and reactive glucose lowering effect. The suppositories were well

In her new position, Ms LaBate will be responsible for providing day-to-day oversight and support to all of Genesis’s regional vice presidents of operations and administrators in six